Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by US Bancorp DE (2024)

US Bancorp DE lowered its position in Elanco Animal Health Incorporated (NYSE:ELANFree Report) by 11.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,715 shares of the company’s stock after selling 3,228 shares during the period. US Bancorp DE’s holdings in Elanco Animal Health were worth $419,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sapient Capital LLC acquired a new stake in Elanco Animal Health in the fourth quarter valued at $2,046,000. Phocas Financial Corp. acquired a new position in Elanco Animal Health during the fourth quarter worth about $3,857,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Elanco Animal Health during the first quarter worth about $1,226,000. Vanguard Group Inc. lifted its holdings in shares of Elanco Animal Health by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after purchasing an additional 467,196 shares in the last quarter. Finally, Bank of Nova Scotia acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $4,004,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Stock Down 1.7 %

ELAN stock opened at $12.81 on Friday. The company has a 50 day moving average price of $15.97 and a two-hundred day moving average price of $15.56. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.96 and a current ratio of 3.29. The stock has a market capitalization of $6.33 billion, a P/E ratio of -4.83, a PEG ratio of 1.29 and a beta of 1.42. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.80.

Elanco Animal Health (NYSE:ELANGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The business’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.45 earnings per share. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.93 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ELAN shares. Piper Sandler cut their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st. Barclays cut their price target on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, June 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.57.

Read Our Latest Research Report on Elanco Animal Health

Insider Buying and Selling at Elanco Animal Health

In related news, Director William F. Doyle acquired 15,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were acquired at an average cost of $16.98 per share, for a total transaction of $254,700.00. Following the acquisition, the director now directly owns 76,330 shares in the company, valued at approximately $1,296,083.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.57% of the stock is owned by company insiders.

Elanco Animal Health Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Read More

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELANFree Report).

Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by US Bancorp DE (2024)

FAQs

Is Elanco Animal Health a good stock to buy? ›

Elanco Animal Health has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 1 sell ratings. The average price target for Elanco Animal Health is $18.78. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

Why is Elanco stock dropping? ›

However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Zenrelia would come with a boxed warning on safety. As a result of the news, Elanco's stock price declined over 21%, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024.

Is Elanco still owned by Eli Lilly? ›

Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world. Greenfield, Indiana, U.S.

What is the net worth of Elanco Animal Health? ›

Elanco Animal Health has a market cap or net worth of $6.39 billion as of July 23, 2024. Its market cap has increased by 29.26% in one year.

What is the future of Elanco? ›

The Company continues to expect positive differentiation related to effectiveness. “We have a robust innovation portfolio and continue to expect to deliver $600 to $700 million of Innovation sales by the end of 2025,” said Jeff Simmons, Elanco President and CEO.

What is the stock price prediction for Elanco? ›

What are analysts forecasts for Elanco Animal Health stock? The 30 analysts offering price forecasts for Elanco Animal Health have a median target of 16.43, with a high estimate of 23.00 and a low estimate of 9.00. The median estimate represents a 78.29 difference from the last price of 12.87.

Why did Bayer sell to Elanco? ›

A $7 billion pet healthcare acquisition

Elanco pursued the Bayer merger for two key reasons. The first is that historically, Elanco has been focused on supplying the livestock animal healthcare market, but wanted to expand its reach into the faster-growing pet healthcare market.

Is Elanco a profitable company? ›

Gross profit was $690 million, or 57.3% of revenue on both a reported and adjusted basis in the first quarter of 2024.

Is Bayer now Elanco? ›

GREENFIELD, Ind. --(BUSINESS WIRE)-- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health.

What was the old name of Elanco? ›

The Elanco brand, short for Eli Lilly and Company, came to be in 1960, following the reorganization of Eli Lilly and Company's Agricultural and Industrial Sales Division.

Did Elanco split from Lilly? ›

Elanco Animal Health completes separation from Lilly Elanco Animal Health completes separation from Lilly. Elanco a fully independent company now that Eli Lilly has completed exchange offer. Elanco Animal Health Inc. announced March 11 that it is now a fully independent company.

Where is Elanco moving to? ›

Purdue and Elanco have committed to develop a new shared-use facility on 3 acres in the One Health Innovation District near the future Elanco global headquarters on the western edge of the White River in Indianapolis.

How much does the CEO of Elanco make a year? ›

Management criteria checks 2/4. Elanco Animal Health's CEO is Jeff Simmons, appointed in Jul 2018, has a tenure of 5.83 years. total yearly compensation is $13.66M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options.

How big is Elanco Animal Health? ›

Fourth Quarter 2023 Financial Results: Revenue of $1,035 million. Reported Net Loss of $141 million, Adjusted Net Income of $39 million.

Is Elanco in the Fortune 500? ›

(Inside INdiana Business) — For the first time since becoming an independent company, Greenfield-based Elanco Animal Health (NYSE: ELAN) has been added to the Fortune 1000, a list of the largest U.S. incorporated companies published by Fortune magazine. The company ranks number 768.

What is the stock price forecast for Elanco in 2025? ›

Elanco Animal Health Stock Prediction 2025

The Elanco Animal Health stock prediction for 2025 is currently $ 12.22, assuming that Elanco Animal Health shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -7.87% increase in the ELAN stock price.

What is the best health stock to invest in? ›

19 Best Healthcare Stocks to Invest In
Company NameTickerIndustry
PfizerPFEDrug Manufacturers—General
Roche HoldingRHHBYDrug Manufacturers—General
SanofiSNYDrug Manufacturers—General
HaleonHLNDrug Manufacturers—Specialty and Generic
15 more rows

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Amb. Frankie Simonis

Last Updated:

Views: 6094

Rating: 4.6 / 5 (56 voted)

Reviews: 87% of readers found this page helpful

Author information

Name: Amb. Frankie Simonis

Birthday: 1998-02-19

Address: 64841 Delmar Isle, North Wiley, OR 74073

Phone: +17844167847676

Job: Forward IT Agent

Hobby: LARPing, Kitesurfing, Sewing, Digital arts, Sand art, Gardening, Dance

Introduction: My name is Amb. Frankie Simonis, I am a hilarious, enchanting, energetic, cooperative, innocent, cute, joyous person who loves writing and wants to share my knowledge and understanding with you.